RBC Capital Reiterates Outperform on ADC Therapeutics, Maintains $8 Price Target
ADC Therapeutics Analyst Ratings
Fulcrum Therapeutics Analyst Ratings
BWS Financial Maintains Buy on Hawkins, Maintains $160 Price Target
Hawkins Analyst Ratings
ZSPACE Analyst Ratings
Precigen Analyst Ratings
Mizuho Maintains Neutral on New Jersey Resources, Lowers Price Target to $50
LM Funding America Outlines Immersion Mining Expansion and $15.5M Bitcoin Holdings Value Amid Operational Efficiency Drive
Mizuho Maintains Outperform on Harmony Biosciences Hldgs, Raises Price Target to $48
Wedbush Reiterates Outperform on Jade Biosciences, Maintains $17 Price Target
Harmony Biosciences Hldgs Analyst Ratings
Zenas BioPharma, Inc. GAAP EPS of -$0.80, Revenue of $10M
Jade Biosciences Analyst Ratings
Alto Neuroscience Analyst Ratings
Elevation Oncology Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 EPS Results.
Citigroup Maintains Buy on Allogene Therapeutics, Lowers Price Target to $4
B of A Securities Maintains Buy on Phinia, Raises Price Target to $55
Phinia Analyst Ratings
ScPharmaceuticals Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Sales Results.